Health Catalyst Appoints Ben Albert as Chief Executive Officer

Albert to Sharpen Focus on Improving Cost and Operational Efficiency, Clinical Quality, and Consumer Experience in Healthcare Health Catalyst Board to be Reduced to Five Directors Immediately Prior to the 2026 Annual Meeting SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Health Catalyst, Inc. (Nasdaq: HCAT) ("Health Catalyst" or the "Company"), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Ben Albert, the Company's President and Chief Operating Officer (COO), was appointed to serve as Chief Executive Officer (CEO) and as a member of Health Catalyst's Board of Directors ( "Board"), effective February 12, 2026. In connection with the appointment, Health Catalyst accelerated the timing of its previously announced succession plan for Dan Burton, who has stepped down as CEO and as a member of the Board.

PRNewsWire • Feb 18, 2026

Down 20.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround

Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Feb 16, 2026

Down 21.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround

Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Feb 13, 2026

Here's Why Health Catalyst (HCAT) Is a Great 'Buy the Bottom' Stock Now

Health Catalyst (HCAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research • Jan 28, 2026

Matt Arens, CEO and Founder of Health Catalyst's Largest Shareholder, First Light Asset Management, Joins Board of Directors

SALT LAKE CITY , Dec. 2, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst" or the "Company," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Matt Arens, CEO and Founder of First Light Asset Management, LLC ("First Light"), has been appointed to serve as a member of Health Catalyst's board of directors ("Board"), effective Dec. 1, 2025. A shareholder since Health Catalyst's IPO in 2019, First Light is the Company's largest shareholder, and First Light and Mr.

PRNewsWire • Dec 2, 2025

Health Catalyst to Participate in Upcoming Investor Conferences

SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that members of senior management will participate in the following upcoming investor conferences: The Stephens Annual Investment Conference, being held in Nashville, including a fireside chat with Ben Albert, President and Chief Operating Officer, Jason Alger, Chief Financial Officer, and Matt Hopper, SVP of Finance and Head of Investor Relations, on Wednesday, November 19, 2025 at 3:00pm CT. The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held in New York, including 1x1 meeting opportunities with Dan Burton, Chief Executive Officer, Ben Albert, President and Chief Operating Officer, Jason Alger, Chief Financial Officer, and Matt Hopper, SVP of Finance and Head of Investor Relations, on Thursday, November 20, 2025.

GlobeNewsWire • Nov 14, 2025

Health Catalyst, Inc. (HCAT) Q3 2025 Earnings Call Transcript

Health Catalyst, Inc. ( HCAT ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Matt Hopper Daniel Burton - CEO & Director Benjamin Albert - President & COO Jason Alger - Chief Financial Officer Conference Call Participants Jared Haase - William Blair & Company L.L.C., Research Division Jessica Tassan - Piper Sandler & Co., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Richard Close - Canaccord Genuity Corp., Research Division Daniel Grosslight - Citigroup Inc., Research Division David Larsen - BTIG, LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Jeffrey Garro - Stephens Inc., Research Division Gabrielle Ingoglia - Cantor Fitzgerald & Co., Research Division Presentation Operator Welcome to the Health Catalyst Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 11, 2025

Health Catalyst Reports Third Quarter 2025 Results

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2025. “For the third quarter of 2025, I am pleased by our financial results, including total revenue of $76.3 million and Adjusted EBITDA of $12.0 million, with these results beating our quarterly guidance on each measure,” said Dan Burton, CEO of Health Catalyst.

GlobeNewsWire • Nov 10, 2025

Health Catalyst (HCAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Nov 11, 2025

Health Catalyst (HCAT) Q3 Earnings and Revenues Top Estimates

Health Catalyst (HCAT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Nov 11, 2025